Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | AKT2 | P31751 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28062247 | 0.78 | CYP2A6 (0.45) | MAPTLMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5953671 | 0.77 | TSHR (0.39) | MAPTLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL28176610 | 0.76 | ADORA2A (0.34) | MAPTBRD4AKT2CHEK1BRD2 | |
| SCHEMBL4322699 | 0.74 | ALDH1A1 (0.33) | MAPTAKT2ESR2ALDH1A1CYP2A6 | |
| SCHEMBL11487737 | 0.73 | CYP1A2 (0.41) | BRD4KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL9453784 | 0.73 | MAPT (0.40) | MAPTLMNAHTTBRD4AKT2 | |
| SCHEMBL20873646 | 0.72 | MAPT (0.43) | MAPTLMNAHTTBRD4AKT2 | |
| SCHEMBL317298 | 0.71 | RAPGEF4 (0.33) | — | |
| SCHEMBL8763856 | 0.71 | DHFR (0.37) | MAPTLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1133458 | 0.70 | PSMB5 (0.46) | MAPTLMNAHTTBRD4AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203745-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2009-08-13 | — | — | US | claimed |
| CN-109311844-B | Triazine compound, method for producing same, and organic electroluminescent element containing same as constituent component | 东曹株式会社 | 2021-07-20 | — | — | CN | disclosed |
| US-8871877-B2 | Hybrid organic-inorganic materials that contain stabilized carbene | UNIVERSITE CLAUDE BERNARD LYON 1 (UCBL) (FR) | 2014-10-28 | — | — | US | disclosed |
| US-20110160412-A1 | HYBRID ORGANIC-INORGANIC MATERIALS THAT CONTAIN STABILIZED CARBENE | UNIVERSITE CLAUDE BERNARD LYON | 2011-06-30 | — | — | US | disclosed |
| WO-2009092814-A1 | HYBRID ORGANIC-INORGANIC MATERIALS THAT CONTAIN STABILIZED CARBENE | CPE LYON FORMATION CONTINUE ET RECHERCHE (FR) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203745-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | ITGB1, ITGA2, ITGB2 | MAPT 4797/4885LMNA 1498/4885HTT 4786/4885 |
| US-20110160412-A1 | HYBRID ORGANIC-INORGANIC MATERIALS THAT CONTAIN STABILIZED CARBENE | VIM, OSTC, ORC3 | MAPT 978/4885LMNA 4458/4885HTT 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.